2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants
- 6 February 2018
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 38 (3) , 977-1002
Abstract
Chronic hepatitis B (CHB) is one of the major causes of morbidity and mortality worldwide. Currently, clinically approved nucleos(t)ide analogs (NAs) are very efficient in reducing the load of hepatitis B virus (HBV) with minimum side effects. However, the long‐term administration of antiviral drugs promotes HBV for potential drug resistance. To overcome this problem, combination therapies are administered, but HBV progressively altered mutations remain a threat. Therefore, optimally designed NAs are urgently needed to treat drug‐resistant HBV. Herein, 2′‐fluoro‐6′‐methylene carbocyclic adenosine (FMCA) and its phosphoramidate (FMCAP) have been discovered, which may be utilized in combination therapies for curing drug‐resistant chronic hepatitis B. In preclinical studies, these carbocyclic NAs demonstrated potential anti‐HBV activity against adefovir, as well as lamivudine (LMV/LAM) drug‐resistant mutants. In vitro, these molecules have demonstrated significant activity against LMV/entecavir (ETV) triple mutants (L180M + S202G + M204V). Also, preliminary studies of FMCA/FMCAP in chimeric mice and female Non‐obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse models having the LMV/ETV triple mutant have shown a high rate of reduction of HBV DNA levels compared to ETV. In this review, we have summarized preclinical studies of FMCA and its phosphoramidate prodrug (FMCAP).Keywords
This publication has 133 references indexed in Scilit:
- Hepatitis B virus resistance to antiviral drugs: where are we going?Liver International, 2011
- Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus InfectionsClinical Microbiology Reviews, 2011
- Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B PatientsJournal of Virology, 2010
- Selection and Counterselection of the rtI233V Adefovir Resistance Mutation during Antiviral TherapyJournal of Clinical Microbiology, 2010
- Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking SimulationAntimicrobial Agents and Chemotherapy, 2010
- Morphogenesis of hepatitis B virus and its subviral envelope particlesCellular Microbiology, 2009
- Antiviral resistance and hepatitis B therapy #Hepatology, 2009
- Hepatitis B: The virus and disease #Hepatology, 2009
- The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In VitroAntimicrobial Agents and Chemotherapy, 2007
- Inhibition of Hepatitis B Virus Polymerase by EntecavirJournal of Virology, 2007